Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol Myers Squibb (NYSE: BMY) generates frequent news across drug development, regulatory milestones, clinical data and corporate actions, reflecting its role as a global biopharmaceutical company focused on serious diseases. News coverage on this page centers on how the company’s cardiovascular, oncology, hematology, immunology and neuroscience programs progress from clinical trials to regulatory decisions and real-world use.
Recent updates have highlighted positive Phase 3 trial results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy in the SCOUT-HCM study, including statistically significant improvements in left ventricular outflow tract gradients and safety findings consistent with adult experience. Other headlines feature regulatory developments such as the U.S. Food and Drug Administration granting priority review to an Opdivo (nivolumab) plus chemotherapy combination for previously untreated advanced classical Hodgkin lymphoma, and the FDA’s approval of Breyanzi (lisocabtagene maraleucel; liso-cel) for adults with relapsed or refractory marginal zone lymphoma.
Investors and followers of BMY can also expect news on hematology research presented at major medical meetings, including data on investigational targeted protein degradation agents like golcadomide and BMS-986458, and long-term follow-up results for Breyanzi in large B-cell and follicular lymphomas. Corporate and financial items appear as well, such as dividend declarations, debt offerings, tender offers for outstanding notes, and presentations at healthcare investment conferences.
This news feed brings together company press releases, clinical trial readouts, regulatory updates, access and affordability agreements, and SEC-reported events. For users tracking BMY stock, it offers a single place to review how Bristol Myers Squibb’s pipeline, marketed products and capital markets activity evolve over time. Bookmark this page to quickly review new trial results, FDA decisions, access initiatives and financial disclosures related to Bristol Myers Squibb.
PureTech Health announced that KarXT, now marketed as Cobenfy, has received FDA approval for treating schizophrenia in adults. This milestone triggers $29 million in payments to PureTech and unlocks potential future payments and royalties. Cobenfy, invented by PureTech, is the first new drug mechanism approved in over 50 years for schizophrenia treatment.
The approval validates PureTech's unique R&D model, which has now produced three FDA-approved therapeutics. PureTech has generated approximately $1.1 billion from its involvement with Karuna Therapeutics, which was recently acquired by Bristol Myers Squibb. This success enables PureTech to self-fund the advancement of several programs, including LYT-100 for idiopathic pulmonary fibrosis, with topline data expected by year-end.
Bristol Myers Squibb (NYSE: BMY) has received FDA approval for COBENFY™ (xanomeline and trospium chloride), a first-in-class oral medication for treating schizophrenia in adults. This groundbreaking approval marks the first new pharmacological approach to schizophrenia treatment in decades, targeting M1 and M4 receptors without blocking D2 receptors.
The approval is based on the EMERGENT clinical program, which demonstrated significant reductions in schizophrenia symptoms compared to placebo. In Phase 3 trials, COBENFY showed 9.6-point and 8.4-point reductions in PANSS total scores compared to placebo at week five.
COBENFY's safety profile has been established in acute and long-term trials. Common adverse reactions include nausea, dyspepsia, and constipation. The drug does not carry atypical antipsychotic class warnings or a boxed warning.
Bristol Myers Squibb (NYSE: BMY) announced new data from the Phase 3 DAYBREAK trial for Zeposia (ozanimod) in treating relapsing forms of multiple sclerosis. The study demonstrated:
1. Sustained decreased rates of brain volume loss for up to 5 years of continuous treatment.
2. Low and stable rates of whole brain volume loss through Month 60.
3. Declining or stable incidence rates of treatment-emergent adverse events over 8+ years.
4. Consistent reductions in brain volume loss when switching from interferon beta-1a to Zeposia.
The data reinforces Zeposia's established safety and efficacy profile as an effective oral therapy for multiple sclerosis, particularly for newly diagnosed patients.
Bristol Myers Squibb (NYSE: BMY) released 10-year follow-up data from the CheckMate -067 Phase 3 trial showing continued long-term survival benefits of Opdivo® plus Yervoy® in advanced melanoma patients. At ten years, 43% of patients treated with the combination were still alive, compared to a 1-year survival rate of 25% a decade ago. Results showed a median overall survival (OS) of 71.9 months for the combination therapy, 36.9 months for Opdivo alone, and 19.9 months for Yervoy alone. These findings were presented at the ESMO Congress 2024 and published in The New England Journal of Medicine. The study included 945 patients, highlighting that durable clinical benefits were observed across subgroups, including those with BRAF mutant and wild-type tumors. Safety data showed no new adverse signals, and Grade 3/4 treatment-related adverse events were consistent with prior findings.
Bristol Myers Squibb (NYSE: BMY) has announced that it will release its third quarter 2024 financial results on Thursday, October 31, 2024. The company will host a conference call and live webcast at 8:00 a.m. ET on the same day to discuss the results and address questions from investors and analysts. Interested parties can listen to the webcast at http://investor.bms.com or register for the live call. A replay of the webcast and conference call will be available until November 14, 2024. This announcement provides investors and analysts with an opportunity to gain insights into BMY's financial performance and future outlook.
Bristol Myers Squibb (NYSE: BMY) has announced its latest dividend declarations. The Board of Directors has declared a quarterly dividend of $0.60 per share on the company's common stock, payable on November 1, 2024, to stockholders of record as of October 4, 2024. Additionally, a quarterly dividend of $0.50 per share has been declared on the company's convertible preferred stock, payable on December 2, 2024, to stockholders of record as of November 5, 2024. These dividend announcements demonstrate BMY's commitment to returning value to shareholders and maintaining its dividend program.
Bristol Myers Squibb (NYSE: BMY) announced it will present nearly 60 abstracts at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, from September 13-17.
Key highlights include:
- Data from the Phase 2 RELATIVITY-104 trial indicating the efficacy of nivolumab, relatlimab, and chemotherapy as a first-line treatment for stage IV or recurrent NSCLC.
- Plans to initiate Phase 3 RELATIVITY-1093 trial.
- Ten-year follow-up data from CheckMate-067 showing long-term survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) in advanced melanoma.
- Results from early-phase trials supporting BMS's diverse oncology portfolio and novel combinations across a wide range of solid tumors.
An investor webcast will be hosted on September 14 to discuss these advancements.
Bristol Myers Squibb (NYSE: BMY) employees are embarking on the Coast 2 Coast 4 Cancer (C2C4C) cycling event, aiming to raise $1 million for the V Foundation for Cancer Research. The 3,000-mile relay from Oregon to New Jersey involves teams cycling approximately 225 miles each over three days. Since 2014, C2C4C has raised over $12.7 million for cancer research in North America. Bristol Myers Squibb will match donations up to $500,000. The event has expanded globally, with rides in Europe, Japan, and Latin America, contributing to a total of $16 million USD donated worldwide for cancer research. Many participants have personal connections to cancer, riding in memory of loved ones or as survivors themselves.
Bristol Myers Squibb (NYSE: BMY) announced new long-term follow-up results from the EXPLORER-LTE study of CAMZYOS® (mavacamten) in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The data, presented at the European Society of Cardiology Congress, showed consistent and sustained improvements in echocardiographic measures and symptoms after up to 3.5 years of treatment. Key findings include:
- Reductions in left ventricular outflow tract (LVOT) gradients and left atrial volume index
- Decreased NT-proBNP levels
- Improvement in NYHA class, with 66.3% of patients reaching class I at Week 180
- No new safety signals identified
The results reinforce CAMZYOS's established efficacy and safety profile as the first approved cardiac myosin inhibitor for symptomatic oHCM.
Bristol Myers Squibb (NYSE: BMY) has announced its participation in two upcoming investor conferences in September 2024. Christopher Boerner, Board Chair and CEO, and David Elkins, EVP and CFO, will engage in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5 at 1:05 p.m. ET. Adam Lenkowsky, EVP and Chief Commercialization Officer, will participate in a similar session at the 2024 Wells Fargo Healthcare Conference on September 6 at 9:30 a.m. ET.
Both sessions will be accessible to investors and the public via http://investor.bms.com. Archived versions will be available after the events conclude. These conferences provide an opportunity for BMY to address questions about the company and engage with the investment community.